EMA Authorised: Libmeldy (atidarsagene autotemcel) — Orchard Therapeutics (Netherlands) B.V.

View source ↗

Summary

The European Medicines Agency authorised Libmeldy (atidarsagene autotemcel) from Orchard Therapeutics (Netherlands) B.V. for metachromatic leukodystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metachromatic Leukodystrophy

Drugs mentioned

• Libmeldy (atidarsagene autotemcel)

Snippet

Status: Authorised. Therapeutic area: Leukodystrophy, Metachromatic. MAH: Orchard Therapeutics (Netherlands) B.V.. Decision date: 15/12/2025. Orphan medicine